196-210 of 811
Improving Health Literacy to Empower Adolescents With Sickle Cell Disease
Project Oncology®Improving Health Literacy to Empower Adolescents With Sickle Cell Disease
Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Project Oncology®Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Balancing Benefits and Risks in Emerging Sickle Cell Therapies
Project Oncology®Balancing Benefits and Risks in Emerging Sickle Cell Therapies
The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease
Project Oncology®The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease
Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions
Project Oncology®Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions
Building a Multidisciplinary Care Team for Sickle Cell Disease Patients
Project Oncology®Building a Multidisciplinary Care Team for Sickle Cell Disease Patients
- advertisement
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Clinician's RoundtableConsensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Clinician's RoundtableTargeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Project Oncology®Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
- advertisement
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate CancerNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
On the Frontlines of Prostate CancerWhy Words Matter: Rethinking Terminology in Advanced Prostate Cancer
